← All indications
Thromboembolism
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
Subtype terms (3)
More specific conditions that are subtypes of Thromboembolism in the MeSH hierarchy.
- Embolism, Paradoxical
2 drugs approved
- Intracranial Embolism and Thrombosis
1 drug approved
- Venous Thromboembolism
59 drugs (32 approved, 27 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (22)
Phase 3 trials (10)
Phase 2 trials (10)
Phase 1 trials (4)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (100)
- DuPont
- Daiichi Sankyo
- Eisai
- Bristol-Myers Squibb
- AstraZeneca
- Pfizer
- Sanofi
- Bayer
- GlaxoSmithKline
- Les Laboratoires des Médicaments Stériles
- Medical Compression Systems
- Danish Heart Foundation
- National Heart, Lung, and Blood Institute (NHLBI)
- United States Air Force
- University Hospital, Bonn
- Huazhong University of Science and Technology
- Allegiance Health
- Harvard University
- Duke University
- D'Annunzio University of Chieti–Pescara
- Gruppo Oncologico Italiano di Ricerca Clinica
- Guangzhou Medical University
- Inonu University
- Johns Hopkins University
- Lebanese American University
- Loyola University
- McMaster University
- National University of Malaysia
- Northwell Health
- Qingdao University
- +70 more
Organization Involved with Phase 3 Indications (107)
- Ekos Corp
- Celgene
- Astellas
- Genentech
- AIO-Studien-gGmbH
- ARYx Therapeutics
- Novartis
- Armetheon Inc
- Boston Scientific Corporation
- Cristália Produtos Químicos Farmacêuticos Ltda.
- Hamilton Health Sciences Corporation
- Italfarmaco
- Portola Pharmaceuticals
- Rovi Pharmaceuticals Laboratories
- National Cancer Institute (NCI)
- National Cancer Institute, France
- Velindre NHS Trust
- Unity Health Toronto
- Nova Scotia Health Authority
- Air Force Military Medical University, China
- Academic and Community Cancer Research United
- Rockefeller University
- Anhui Medical University
- Brown University
- Canadian Critical Care Trials Group
- Case Western Reserve University
- Cedars-Sinai Medical Center
- Cancer Research Network
- University of London
- Eastern Virginia Medical School
- +77 more
Organization Involved with Phase 2 Indications (32)
- Takeda
- Archemix Corp.
- BioInvent International AB
- Ionis Pharmaceuticals, Inc.
- vTv Therapeutics
- Fundación Pública Andaluza
- Cornell University
- University of Washington
- Hanyang University
- New York Medical College
- Ohio State University
- University of Hull
- University of Michigan
- University of Science Malaysia
- University of Seville
- University of Southern California
- University of Valencia
- Cardiff University
- University of Colorado, Denver
- Covance
- University of Minnesota
- University of Gothenburg
- Piacenza Hospital
- University of Colorado
- National Institute for Health Research, United Kingdom
- Trillium Health Partners
- Government of Saudi Arabia
- Oxurion NV.
- Tetherex Pharmaceuticals Corporation
- Hôpital Montfort
- +2 more
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (19)
- Prairie Education and Research Cooperative
- Cancer Research Campaign
- Hawler Medical University
- New York University
- Oregon Health and Science University
- Pirogov Russian National Research Medical University
- Swiss Paraplegic Centre Nottwil
- University of Birmingham
- Nazareth Hospital
- Al Mouwasat Hospital
- Alliance Foundation Trials
- National Taiwan University
- Technion University
- Hawler Ministry of Health
- Nazareh Hospital - Mercy Health System
- ARUP Laboratories
- Department of Health and Human Services
- American College of Phlebology
- Chinese Academy of Medical Sciences